» Articles » PMID: 7727781

Lymphoma-associated Translocation T(14;18) in Blood B Cells of Normal Individuals

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 1995 May 1
PMID 7727781
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Successive oncogenic steps are necessary to generate cancer. In many B-cell lymphomas, chromosomal translocations are considered to be an early oncogenic hit. We investigated whether the lymphoma-associated t(14;18) involving the BCL2 oncogene can occur outside the context of malignancy. To this end, we extensively screened blood cells from healthy blood donors by a very sensitive seminested polymerase chain reaction (PCR) for breakpoint junctions at JH1-5 on 14q32 and the major breakpoint region of BCL2 on 18q21. In each individual, mononuclear cells, granulocytes, flow-sorted B cells, and T cells were separately tested in five to seven independently performed PCRs (in total, 0.5 x 10(6) to 1.0 x 10(6) cells per fraction per individual). Amplification products that hybridized with an internal BCL2 probe and a JH probe were sequenced. Six of nine individuals harbored t(14;18) breakpoints. Translocations were restricted to B cells, with an estimated frequency of 1 in 10(5) or less circulating B cells. In total, 23 of 51 experiments on B cells were positive in contrast to 1 of 48 on T cells and 2 of 47 experiments on granulocytes. Consistent with the presence of 4.7% to 13.0% B cells in the mononuclear cell fractions, only very few (4 of 47) tests were positive in these fractions. Sequence analysis showed that four of six individuals harbored two to five unrelated t(14;18)-carrying B-cell clones. All breakpoints had a structure similar to that in follicular lymphoma. We propose that B cells with the t(14;18) translocation are regularly generated in normal individuals, but that only very few cells with the translocation will acquire the additional oncogenic hits necessary to establish the malignant phenotype.

Citing Articles

ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.

Barisic D, Chin C, Meydan C, Teater M, Tsialta I, Mlynarczyk C Cancer Cell. 2024; 42(4):583-604.e11.

PMID: 38458187 PMC: 11407687. DOI: 10.1016/j.ccell.2024.02.010.


Analysis of immunoglobulin/T-cell receptor repertoires by high-throughput RNA sequencing reveals a continuous dynamic of positive clonal selection in follicular lymphoma.

Bobee V, Viennot M, Rainville V, Veresezan L, Drieux F, Viailly P Hemasphere. 2024; 8(2):e50.

PMID: 38435425 PMC: 10896008. DOI: 10.1002/hem3.50.


Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma.

Blanco M, Collazo-Lorduy A, Yanguas-Casas N, Calvo V, Provencio M Cancers (Basel). 2022; 14(9).

PMID: 35565286 PMC: 9102342. DOI: 10.3390/cancers14092158.


B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy.

Alam M, Ali S, Mohammad T, Hasan G, Yadav D, Hassan M Int J Mol Sci. 2021; 22(19).

PMID: 34638779 PMC: 8509036. DOI: 10.3390/ijms221910442.


Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.

Dawes J, Uren A Front Immunol. 2021; 12:670280.

PMID: 34484175 PMC: 8414522. DOI: 10.3389/fimmu.2021.670280.